휴마시스

205470KOSDAQ

59.5 / 100

Reference Date: 2026-10-23

Financial Score25.0 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 12.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

HumaSys operates in three main business segments: POCT immunoassay reagents for in vitro diagnostics, production of male condoms and medical devices, and entertainment services. The POCT division focuses on improving diagnostic products for COVID-19 and HIV, while the rubber products division produces a range of items according to international standards. The entertainment division generates revenue through artist management and content production. Major revenue streams come from POCT (13.4%), rubber products (19.5%), and entertainment services (46.2%).

Number of Employees

64people

Average Salary

47.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.27Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-8.97Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

0.35Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲51.1% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲39.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -13.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position5.0Point

52w mid range (51%)

Current 2,530Won52-week high 4,26552-week low 682

1-month return1.0Point

1m -12.15% (falling)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주주총회소집공고2026-10-21
Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-10-21
Neutral의결권대리행사권유참고서류2026-10-21
Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-10-14